What Biteral Treats: Main Uses and Benefits

The therapeutic scope of Ornidazole (Biteral) is focused on conditions presenting with systemic or localized discomfort associated with specific protozoal and anaerobic bacterial pathogens. The medication is indicated for the management of protozoal diseases and anaerobic bacterial infections. This approach provides support that helps ease the overall symptom burden by managing the pathogenic presence.

The medication is relevant for managing specific conditions including amoebiasis, giardiasis, trichomoniasis, and various deep-seated anaerobic infections in contexts like the abdomen or pelvis. It is also applied in scenarios where additional symptomatic assistance is needed for surgical prophylaxis before high-risk procedures.

Its use is appropriate when infections create noticeable physiological strain and supportive symptom management is required.

---

Quick Fact: Managing Gastrointestinal Distress

Ornidazole is relevant for easing symptom clusters that may become disruptive, such as symptoms related to physical discomfort, including diarrhea, abdominal discomfort, and fever, associated with amoebiasis or giardiasis, and contributes to easing the overall symptom load during symptomatic periods.

Regulatory References

1. Official Drug Authority product summary

Who Can and Cannot Use Biteral (Ornidazole)?

The eligibility profile for Ornidazole is strictly defined by regulatory authorities and centers on absolute prohibitions and conditional use requirements based on the patient's existing health status.

Eligibility Scope	Official Regulatory Status
Populations for whom use is contraindicated	Patients with known hypersensitivity to Ornidazole or other nitroimidazole derivatives (e.g., Metronidazole). Patients with organic central nervous system (CNS) diseases such as epilepsy or disseminated sclerosis. Use is prohibited during the first trimester of pregnancy (as listed by some regulators).
Pregnancy and Lactation Eligibility	Not recommended during pregnancy or while breastfeeding unless absolutely necessary, due to a lack of controlled human safety data. Use during the first trimester is formally contraindicated by some authorities.
Age-Related Eligibility	Adult use is standard. Pediatric use is permitted for specific conditions but is generally restricted by body mass (e.g., contraindicated for children under 6 kg, as per one regulator). Precautions are necessary when administering to elderly patients.
Condition-Specific Restrictions	Severe hepatic impairment requires restricted use, often mandating a doubled dosing interval to prevent drug accumulation. Patients with a history of blood disorders must have their leukocyte counts checked before and after therapy. Treatment must be discontinued if neurological symptoms like ataxia or confusion develop.

Connection to the overall eligibility profile: Regulatory documents precisely define who can and cannot use Ornidazole by establishing absolute contraindications based on drug class hypersensitivity and existing neurological conditions. The profile further mandates conditional use and monitoring for patients with impaired hepatic function, certain blood disorders, or specific age/body weight parameters, ensuring that eligibility is strictly governed by clinical context as outlined in official labels.

The regulatory documentation for Ornidazole outlines specific drug and substance interactions that affect pharmacological effect and systemic exposure. These interactions establish clear restrictions for co-administration.

Prohibited and Restricted Co-administration

Co-administration with Disulfiram is explicitly restricted due to the documented potential risk of developing acute confusion or psychosis. Alcohol (Ethanol) must be avoided entirely during therapy and for a mandatory period, typically stipulated as at least three days following the last dose, based on requirements from certain regulatory authorities.

Interactions Affecting Drug Exposure and Clearance

Certain medicines affect the clearance of Ornidazole. The metabolism inhibitor Cimetidine is reported to decrease plasma clearance and prolong the drug's half-life. Conversely, enzyme-inducing agents such as Phenobarbital and Phenytoin reduce the half-life of Ornidazole. The drug also affects other medicines: it is documented to increase the systemic exposure of Lithium and reduce the clearance of 5-Fluorouracil, raising the risk of toxicity. The effects of Coumarin-type oral anticoagulants are also potentiated, leading to an increased anticoagulant effect.

Pharmacodynamic Effects and Administration Constraints

Ornidazole is documented to prolong the muscle-relaxant effect of Vecuronium bromide (a pharmacodynamic interaction). For specific populations, regulatory constraints note that in patients with severe hepatic impairment, the dosing interval must be doubled to account for the reduced Ornidazole clearance.

The mechanism of Ornidazole (Biteral) is defined by a cascade of selective biochemical events, with the drug acting as an inert prodrug until activated. The initial action begins only when the parent molecule's 5-nitro group is reduced by low-redox potential enzymes, such as ferredoxins, which are unique to anaerobic and microaerophilic organisms. This process converts the molecule into a highly reactive nitro radical anion. This transformation defines how the cytotoxic mechanism is primarily directed toward the target pathogen.

The short-lived, energetic nitro radicals immediately initiate a cytotoxic cascade by chemically binding to the pathogen's DNA. This interaction causes structural fragmentation and damage to the helix, which inhibits essential genetic processes, including replication and transcription, resulting in the death of the microbial cell.

The entire mechanism is functionally dependent on a low-oxygen environment, as high oxygen tension suppresses the necessary initial reductive activation step. This inherent constraint, along with the targeted genetic damage, establishes the drug's selective microbicidal effect on the susceptible microbial population.

The administration of Biteral, which contains the active ingredient Ornidazole, involves specific routes, dosing schedules, and intake conditions. The medicine is available as an oral film-coated tablet and a sterile solution for intravenous (IV) infusion. The oral route is utilized for standard or maintenance therapy, while the IV route is typically reserved for initiating treatment in severe infections, with a transition to the tablet form once a patient’s condition stabilizes.

Dosing patterns involve a short course of therapy, usually lasting from one day up to a maximum of ten days. Frequency varies from a single, high-dose regimen of up to 1.5 g to a standard maintenance pattern of 500 mg taken twice daily (i.e., every 12 hours). Oral tablets are taken after meals (postprandial) and swallowed whole with water. For surgical prophylaxis, the schedule involves a single dose of 1.5 g pre-operatively, followed by a postoperative course.

Adjustments are applied for specific populations. For instance, in patients with severe hepatic impairment (liver dysfunction), the dosing interval is doubled. Individuals undergoing hemodialysis require an additional dose before the procedure to compensate for drug removal. If a dose is missed, the standard practice is to skip the dose if it is close to the time for the next scheduled dose, thereby avoiding a double dose.

Recent Clinical Evidence

---

Research on the Metronidazole and Ofloxacin Combination

Research has evaluated whether the combination of Metronidazole (component A) and Ofloxacin (component B) is associated with an outcome in relation to the symptoms of certain bacterial and parasitic infections. Multiple randomized, controlled trials (RCTs) have been conducted to examine the findings associated with these two agents when administered together.

• Studies examined the combined administration for treating complex or mixed infections, comparing the combination against single-drug regimens.
• The primary endpoint of evaluated studies was often the microbiological cure rate or clinical response, typically assessed over a 7 to 14-day period. Secondary endpoints included time to symptom resolution and adverse event frequency.
• Comparative research has not clearly established whether this specific combination treatment differs significantly from other standard broad-spectrum antimicrobial medications for all evaluated indications.

---

Adverse Event Reporting

Adverse event reporting for the Metronidazole and Ofloxacin combination was conducted during clinical trials involving patient groups. The trials report on the frequency and type of events observed across most individuals.

• Research has reported common adverse events, which typically included gastrointestinal issues (e.g., nausea, diarrhea) and central nervous system effects (e.g., dizziness, headache). Study findings indicated these events were reported as mild to moderate and temporary.
• Serious adverse events were rarely reported in the study population, consistent with the known profiles of the individual components.

---

Limitations of Current Evidence

While research has explored this combination, gaps in the current evidence base remain.

• Most studies have focused on short-term findings related to primary endpoints (up to 14 days). Research has not clearly established the long-term influence of the combination beyond the course of treatment.
• The influence on specific patient groups, such as pediatric populations, is often not fully clear, as these age groups were sometimes excluded from the primary studies.

Key Studies & References

1. Efficacy and safety of different drugs for the treatment of bacterial vaginosis: a systematic review and network meta-analysis
2. Treatment Guidelines for Antimicrobial Use in Common Syndromes 2019 - Indian Council of Medical Research (ICMR)

How to Store and Dispose of Biteral (Ornidazole)

Storage and disposal of Biteral must strictly follow the conditions defined in official regulatory labeling to ensure product stability and patient safety.

Condition	Requirement (Official Labeling)
Temperature Limit	Store at a temperature not exceeding 30 C (86 F).
Protection	Must be protected from light and moisture and kept in a cool, dry place.
Packaging	Keep tablets in the original blister pack until use.
Child Safety	Mandatory to keep out of reach of children.
Disposal	Discard unused or expired product in accordance with local requirements or by consulting a pharmacist.

Storage environments such as bathrooms, cars, or window sills should be avoided to prevent exposure to high heat and humidity. The labeled shelf life for the product is 36 months when stored correctly.